GlassScriptPhysician profile
James Blakeley Long
NPI 1689861635
$1,619.61
in general payments reported to CMS, 2019-2025
21 companies · $40.23 in 2025
The $40.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $190 · 2021: $103 · 2023: $321 · 2024: $708 · 2025: $40.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.93 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.86 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $221.49 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $211.94 | 2023-2025 | |
| Lilly USA, LLC | $173.58 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $119.76 | 2020-2024 | |
| Glaxosmithkline, LLC. | $81.49 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $71.96 | 2020-2023 | Eliquis, Camzyos |
| Amgen INC. | $65.08 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.24 | 2024-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $54.94 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $37.37 | 2020-2021 | |
| Dexcom, INC. | $33.43 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $31.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.59 | 2019-2020 | |
| Genentech USA, INC. | $28.30 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.39 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $23.87 | 2024 | Watchman Flx |
| Mylan Specialty L.P. | $17.96 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $16.10 | 2024 | Voquezna |
| Astellas Pharma US INC | $15.35 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.